Healthcare -
Medical - Devices - NASDAQ - IL
$ 1.03
-3.74 %
$ 11.3 M
Market Cap
-0.34
P/E
1. INTRINSIC VALUE
Balance Sheet
ReWalk Robotics Ltd.
| Current Assets | 21.3 M |
| Cash & Short-Term Investments | 6.75 M |
| Receivables | 6 M |
| Other Current Assets | 8.54 M |
| Non-Current Assets | 9.19 M |
| Long-Term Investments | 0 |
| PP&E | 1.42 M |
| Other Non-Current Assets | 7.78 M |
| Current Liabilities | 10.2 M |
| Accounts Payable | 5.02 M |
| Short-Term Debt | 858 K |
| Other Current Liabilities | 4.34 M |
| Non-Current Liabilities | 1.41 M |
| Long-Term Debt | 22 K |
| Other Non-Current Liabilities | 1.39 M |
EFFICIENCY
Earnings Waterfall
ReWalk Robotics Ltd.
| Revenue | 25.7 M |
| Cost Of Revenue | 17.4 M |
| Gross Profit | 8.22 M |
| Operating Expenses | 27.8 M |
| Operating Income | -19.6 M |
| Other Expenses | 9.39 M |
| Net Income | -28.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ReWalk Robotics Ltd.
| Net Income | -28.9 M |
| Depreciation & Amortization | 3.84 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.28 M |
| Change in Working Capital | -4.97 M |
| Others | 7.08 M |
| Free Cash Flow | -21.7 M |
Wall Street Analysts Price Targets
ReWalk Robotics Ltd.
Wall Street analysts predict an average 1-year price target for LFWD of $13 , with forecasts ranging from
a
low of
$13 to a high of $13 .
LFWD Lowest Price Target
Wall Street Target
13 USD
1162.14%
LFWD Average Price Target
Wall Street Target
13 USD
1162.14%
LFWD Highest Price Target
Wall Street Target
13 USD
1162.14%
4. DIVIDEND
ANALYSIS
LFWD does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ReWalk Robotics Ltd.
Sold
0-3 MONTHS
2.41 K USD 1
3-6 MONTHS
1.66 M USD 1
6-9 MONTHS
7.21 K USD 1
9-12 MONTHS
38.2 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
115 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lifeward Names Mark Grant as New CEO
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
globenewswire.com
- 1 month ago
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd.
globenewswire.com
- 1 month ago
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates
Lifeward (LFWD) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.73 per share a year ago.
zacks.com
- 1 month ago
Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript
Lifeward Ltd. (NASDAQ:LFWD ) Q1 2025 - Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Mike Lawless - CFO Larry Jasinski - CEO Almog Adar - VP, Finance Conference Call Participants Yale Jen - Laidlaw and Company Swayampakula Ramakanth - H.
seekingalpha.com
- 1 month ago
Lifeward Ltd. Reports First Quarter 2025 Financial Results
U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
globenewswire.com
- 1 month ago
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
globenewswire.com
- 1 month ago
Lifeward to Report First Quarter 2025 Financial Results on May 15, 2025
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its first quarter 2025 financial results before the markets open on Thursday, May 15, 2025.
globenewswire.com
- 1 month ago
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
globenewswire.com
- 2 months ago
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.
globenewswire.com
- 2 months ago
LFWD Stock Falls Despite Launch of Next-Generation Mobility ReWalk 7
Lifeward launches ReWalk 7 in the United States, offering advanced mobility, greater control and smarter walking for individuals with spinal cord injuries.
zacks.com
- 2 months ago
Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 15, 2025 (GLOBE NEWSWIRE) -- Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury
globenewswire.com
- 2 months ago
Lifeward Stock Falls Despite FDA Clearance of ReWalk 7 Exoskeleton
LFWD secures FDA clearance for its ReWalk 7 Exoskeleton, introducing enhanced features to empower individuals with spinal cord injury and expand mobility options.
zacks.com
- 3 months ago
8. Profile
Summary
ReWalk Robotics Ltd. LFWD
COUNTRY
IL
INDUSTRY
Medical - Devices
MARKET CAP
$ 11.3 M
Dividend Yield
0.00%
Description
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Contact
3 Hatnufa Street, Yokneam Illit, 2069203
https://www.rewalk.com
IPO
Date
Sept. 12, 2014
Employees
80
Officers
Mr. Lawrence J. Jasinski BS, MBA
Chief Executive Officer & Director
Ms. Jeannine Lynch
Vice President of Market Access & Strategy
Mr. Charles Remsberg
Chief Sales Officer
Mr. Almog Adar
Vice President of Finance & Chief Accounting Officer
Ms. Miri Pariente
Vice President of Operations, Regulatory & Quality
Mr. Michael A. Lawless
Chief Financial Officer
Ms. Judy Kula
Vice President of Customer Service, Human Resources & Business Affairs